gilteritinib-resistant FLT3 mutants

Stable Identifier
R-HSA-9702590
Type
Pathway
Species
Homo sapiens
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.

Literature References
PubMed ID Title Journal Year
27450971 FLT3 Inhibitors for Treating Acute Myeloid Leukemia

Almahayni, MH, Hassanein, M, Ahmed, SO, Gaballa, S, El Fakih, R

Clin Lymphoma Myeloma Leuk 2016
30651634 Targeting FLT3 mutations in AML: review of current knowledge and evidence

Schlenk, RF, Levis, MJ, Daver, N, Russell, NH

Leukemia 2019
29069942 Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia

Deangelo, DJ, Luskin, MR

Expert Rev Hematol 2017
28851395 Molecular targeting in acute myeloid leukemia

Dubielecka, PM, Lim, SH, Raghunathan, VM

J Transl Med 2017
Participants
Participates
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!